Free Trial
NASDAQ:IFRX

InflaRx (IFRX) Stock Price, News & Analysis

$1.59
-0.09 (-5.36%)
(As of 07/17/2024 ET)
Today's Range
$1.59
$1.68
50-Day Range
$1.18
$1.74
52-Week Range
$1.14
$4.30
Volume
56,799 shs
Average Volume
204,307 shs
Market Capitalization
$93.62 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.50

InflaRx MarketRank™ Stock Analysis

Analyst Rating
Strong Buy
3.50 Rating Score
Upside/​Downside
749.1% Upside
$13.50 Price Target
Short Interest
Healthy
0.40% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.95mentions of InflaRx in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.81) to ($0.94) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.54 out of 5 stars

Medical Sector

481st out of 914 stocks

Pharmaceutical Preparations Industry

227th out of 433 stocks

IFRX stock logo

About InflaRx Stock (NASDAQ:IFRX)

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.

IFRX Stock Price History

IFRX Stock News Headlines

InflaRx (NASDAQ:IFRX) Short Interest Up 151.1% in June
Could You Retire on a Single AI Stock (trading for only $15)?
This is the perfect AI stock...And it's currently trading for only $15. With just one investment in this company, you could potentially set yourself up for massive financial gains.
Could You Retire on a Single AI Stock (trading for only $15)?
This is the perfect AI stock...And it's currently trading for only $15. With just one investment in this company, you could potentially set yourself up for massive financial gains.
InflaRx Q1 2024 Earnings Preview
See More Headlines
Receive IFRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for InflaRx and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/08/2024
Today
7/17/2024
Next Earnings (Estimated)
8/08/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:IFRX
Employees
62
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$13.50
High Stock Price Target
$19.00
Low Stock Price Target
$8.00
Potential Upside/Downside
+749.1%
Consensus Rating
Strong Buy
Rating Score (0-4)
3.50
Research Coverage
2 Analysts

Profitability

Net Income
$-46,180,000.00
Pretax Margin
-41,450.93%

Debt

Sales & Book Value

Annual Sales
$70,000.00
Book Value
$1.89 per share

Miscellaneous

Free Float
49,285,000
Market Cap
$93.62 million
Optionable
Optionable
Beta
1.58
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Dr. Niels C. Riedemann M.D. (Age 51)
    Ph.D., Co-Founder, CEO & Executive Director
  • Prof. Renfeng Guo M.D. (Age 54)
    Co-Founder, Chief Scientific Officer & Executive Director
  • Dr. Thomas Taapken Ph.D. (Age 59)
    Chief Financial Officer
  • Ms. Derval O'Carroll (Age 58)
    Senior VP and Global Head of Regulatory Affairs & Compliance
  • Dr. Camilla Chong M.D. (Age 58)
    Chief Medical Officer
  • Mr. Jan Medina CFA
    Head of Investor Relations & VP
  • Mr. Christian Schmid
    VP and Head of Legal Affairs & General Counsel
  • Ms. Nicole Bertsch
    Senior Director & Head of Human Resources
  • Dr. Maria Habel PH.D. (Age 42)
    VP, Head of Preclinical R&D and QC
  • Dr. Bruce P. Burnett Ph.D.
    VP & Head of Medical Affairs

IFRX Stock Analysis - Frequently Asked Questions

How have IFRX shares performed this year?

InflaRx's stock was trading at $1.63 at the start of the year. Since then, IFRX stock has decreased by 2.5% and is now trading at $1.59.
View the best growth stocks for 2024 here
.

How were InflaRx's earnings last quarter?

InflaRx (NASDAQ:IFRX) released its quarterly earnings data on Wednesday, May, 8th. The company reported ($0.19) EPS for the quarter, topping analysts' consensus estimates of ($0.24) by $0.05. The company earned $0.04 million during the quarter, compared to analyst estimates of $1.76 million.

When did InflaRx IPO?

InflaRx (IFRX) raised $100 million in an initial public offering (IPO) on Wednesday, November 8th 2017. The company issued 6,700,000 shares at $14.00-$16.00 per share. J.P. Morgan, Leerink Partners and BMO Capital Markets served as the underwriters for the IPO.

How do I buy shares of InflaRx?

Shares of IFRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of InflaRx own?

Based on aggregate information from My MarketBeat watchlists, some other companies that InflaRx investors own include Dynavax Technologies (DVAX), Gilead Sciences (GILD), ImmunoGen (IMGN), Inovio Pharmaceuticals (INO), AbbVie (ABBV), OPKO Health (OPK) and Capricor Therapeutics (CAPR).

This page (NASDAQ:IFRX) was last updated on 7/18/2024 by MarketBeat.com Staff

From Our Partners